As research into the BRAF-V600E gene mutation continues, the use of targeted therapeutic agents for this mutation in ameloblastoma is expected to become a valuable adjuvant treatment to reduce the recurrence rate of patients. This evidence concerns the gene BRAF and ameloblastoma.